<b><i>Introduction:</i></b> Renal dysfunction at presentation is uncommon in primary membranous nephropathy (PMN). The data on the outcome of PMN patients with renal dysfunction at outset are scarce. The objective of the current study was to report the clinical outcomes of PMN patients with renal dysfunction. <b><i>Material and Methods:</i></b> This prospective longitudinal observational study included PMN patients (both incident and treatment resistant) with an estimated glomerular filtration rate of &#x3c;60 mL/min/1.73 m². Immunosuppressive treatment was as per the unit’s protocol. Patients were evaluated for proteinuria, creatinine, and serum albumin at monthly intervals for 6 months, then quarterly for a year, and then biannually. Both serum and tissue anti-PLA2R were performed at baseline. Outcome: Percentage of patients achieving clinical remission. <b><i>Results:</i></b> Sixty-four adults met study criteria and were analysed. The median (IQR) age of the patients was 48 (40, 56) years. PMN was PLA2R related in 52 (81.3%) patients. Twenty-eight (43.8%) and 30 (46.9%) patients were in remission at 12 months and at the end of the study [median (IQR) follow up: 24 months (12, 35)], respectively. Eight (12.5%) had progressed to end-stage renal disease at the last follow-up. Median (IQR) baseline anti-PLA2R titre was 150.1 RU/mL (38.5, 308). Nineteen (61.3%) and 18 (58.1%) patients with &#x3e;90% reduction in anti-PLA2R titres at 12 months were in clinical remission at 12 months and at the end of the follow-up, respectively. Both cyclical cyclophosphamide/steroids (cCYC/GC) and rituximab were equally effective in inducing remission, but rituximab had a favourable adverse event profile compared to cCYC/GC. <b><i>Conclusion:</i></b> To conclude, both cCYC/GC and rituximab are equally effective in inducing remission of nephrotic state with compromised renal function due to PMN. Immunosuppression induces remission in up to 50% PMN patients with CKD-stage 3–4.

Introduction: For development of Type 2 Diabetes mellitus, Vitamin D is thought to be a risk factor. Various studies have established the fact that Vitamin D replenishment improves glycemic status and insulin secretion in patients with Type 2 Diabetes mellitus with established hypovitaminosis D. This study was done to find out the degree of association between glycemic status and vitamin D levels in type 2 Diabetes Mellitus patients in a tertiary care center. Patient and methods: The study was done in the Department of Biochemistry, SCB Medical College, and Cuttack 48 patients of type 2 Diabetes Mellitus were taken as cases 42 healthy subjects were taken as controls. Biochemical parameters like FBS, PPBS, Urea, Creatinine, HbA1c, Lipid profile parameters were measured in both cases and controls. Results: The serum urea and creatinine levels were significantly elevated in complicated type 2 Diabetes mellitus patients as compared to healthy controls. Serum cholesterol, triglycerides, LDL Cholesterol levels also showed significant increase Vitamin D and FBS levels showed a significant negative correlation in cases and vitamin D levels were decreased in cases as compared to controls. Conclusion: As Vitamin D and FBS levels showed a significant negative correlation, and vitamin D levels were decreased in cases as compared to controls, so it can be proved that vitamin D can lead to good glycemic control and hypovitaminosis D can thereby lead to Type 2 Diabetes Mellitus.

Searching the recent literature revealed that thyroid dysfunction is related to fibrin formation and fibrinolysis. Few studies proposed that there was an increase in